Tsang P K, Larew J S, Larew L A, Miyakawa T W, Hofer J D
Lilly Research Laboratories, Eli Lilly and Company, Lafayette, IN 47902, USA
J Pharm Biomed Anal. 1998 Mar;16(7):1125-41. doi: 10.1016/s0731-7085(97)00266-5.
Assessment of analytical variability is recognized as an important factor for the establishment of specifications. Estimation of the variance for an analytical procedure can be accomplished using a variety of approaches. The approach of variance component analysis was applied retrospectively, as well as prospectively, to estimate analytical variance. The prospective approach also included the use of experimental design. Recent new drug substance examples illustrating these approaches are presented. In these examples, the analytical property of potency was evaluated. Factors examined in the experimental design include laboratory, day, analyst, instrument and column. Process variability can also be determined by variance component analysis. For a stable drug substance, combining the analytical and process variances provides an estimate on the total variance for the analytical property of potency. With the total variability statistically derived, an appropriate specification that is consistent with process and analytical capability can be established.
分析变异性评估被认为是制定质量标准的一个重要因素。可以使用多种方法来估计分析程序的方差。方差分量分析方法既可以回顾性地应用,也可以前瞻性地应用,以估计分析方差。前瞻性方法还包括实验设计的使用。本文给出了说明这些方法的近期新原料药实例。在这些实例中,对效价这一分析特性进行了评估。实验设计中考察的因素包括实验室、日期、分析人员、仪器和色谱柱。过程变异性也可以通过方差分量分析来确定。对于一种稳定的原料药,将分析方差和过程方差相结合可得出效价分析特性的总方差估计值。基于统计得出的总变异性,可以建立一个与过程和分析能力相一致的合适质量标准。